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OBJECTIVES The Women’s Ischemia Syndrome Evaluation (WISE) is a National Heart, Lung and Blood
Institute–sponsored, four-center study designed to: 1) optimize symptom evaluation and
diagnostic testing for ischemic heart disease; 2) explore mechanisms for symptoms and
myocardial ischemia in the absence of epicardial coronary artery stenoses, and 3) evaluate the
influence of reproductive hormones on symptoms and diagnostic test response.
BACKGROUND Accurate diagnosis of ischemic heart disease in women is a major challenge to physicians, and
the role reproductive hormones play in this diagnostic uncertainty is unexplored. Moreover,
the significance and pathophysiology of ischemia in the absence of significant epicardial
coronary stenoses is unknown.
METHODS The WISE common core data include demographic and clinical data, symptom and
psychosocial variables, coronary angiographic and ventriculographic data, brachial artery
reactivity testing, resting/ambulatory electrocardiographic monitoring and a variety of blood
determinations. Site-specific complementary methods include physiologic and functional
cardiovascular assessments of myocardial perfusion and metabolism, ventriculography, endo-
thelial vascular function and coronary angiography. Women are followed for at least 1 year to
assess clinical events and symptom status.
RESULTS In Phase I (1996–1997), a pilot phase, 256 women were studied. These data indicate that the
WISE protocol is safe and feasible for identifying symptomatic women with and without
significant epicardial coronary artery stenoses.
CONCLUSIONS The WISE study will define contemporary diagnostic testing to evaluate women with
suspected ischemic heart disease. Phase II (1997–1999) is ongoing and will study an
additional 680 women, for a total WISE enrollment of 936 women. Phase III (2000) will
include patient follow-up, data analysis and a National Institutes of Health WISE workshop.
(J Am Coll Cardiol 1999;33:1453–61) © 1999 by the American College of Cardiology
Each year in the U.S., nearly 250,000 women die of
ischemic heart disease, and roughly 100,000 deaths occur
before the average life expectancy, making it the leading
killer of women (1). Although recent data demonstrate that
rates of cardiac catheterization and diagnosis of nonfatal
ischemic heart disease have doubled among women in the
last decade (2), ischemic heart disease in women is still
identified less often (3,4) and at a more advanced stage (5),
and treated less aggressively (4,6) compared with that in
men. Women with ischemic heart disease also have a worse
prognosis compared with their male counterparts (7,8),
suggesting that gender-related differences in disease detec-
tion and treatment may influence prognosis.
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Accurate and timely diagnosis of ischemic heart disease in
women is a major challenge to physicians. At least three
problematic areas exist:
Symptom recognition: Women have a higher frequency
of chest pain than men, yet have a lower prevalence of
epicardial coronary artery stenoses (9). Chest pain/
discomfort characteristic for angina is a less specific
marker for ischemic heart disease in women compared
with that in men (10). Gender-specific ischemic heart
disease symptom tools are not available.
Diagnostic testing: Electrocardiographic (ECG) abnor-
malities, including rest- and exercise-induced changes
indicative of ischemic heart disease, are believed to be
more often “falsely positive” in women than in men
(11). Myocardial perfusion (3), hemodynamic and
ventriculographic response (12) to exercise is more
commonly abnormal among women, without evi-
dence of epicardial coronary artery stenoses, compared
with that among men. Prognosis in women with
symptoms and abnormal diagnostic tests but no cor-
onary stenoses is largely unknown. Existing diagnostic
testing modalities for both epicardial coronary artery
disease and microvascular dysfunction are suboptimal
in women.
Reproductive hormonal status: Diagnostic testing for
ischemic heart disease in women demonstrates higher
levels of test variability compared with that in men
(13). Cycling reproductive hormones may account for
this variability. Effects of fluctuating estrogen levels
on vascular smooth muscle and coronary artery vaso-
motion have been postulated as explanations for why
women have a higher frequency of chest pain and
more frequent false positive stress test results in the
absence of epicardial coronary artery disease compared
with men. Experimental data show that estrogen
affects coronary artery vasomotor function (14). The
role reproductive hormones play in symptom mani-
festation and ischemic heart disease diagnostic testing
is largely unknown.
The Women’s Ischemia Syndrome Evaluation (WISE) is
a National Heart, Lung and Blood Institute–sponsored,
four-center study designed to address ischemic heart disease
recognition and diagnosis. The primary objectives of the
WISE are: 1) to improve diagnostic testing for ischemic
heart disease in women, including symptom evaluation
tools, risk assessment algorithms and noninvasive imaging
techniques; 2) to study pathophysiologic mechanisms and
prognosis in women with chest pain and abnormal diagnos-
tic testing for myocardial ischemia in the absence of epicar-
dial coronary artery stenoses, and 3) to evaluate the influ-
ence of cyclical hormones, menopausal status and
reproductive hormone levels on symptoms and diagnostic
testing results.
METHODS
The WISE study design brings together a variety of
expertise (Appendix) to assess different but complementary
innovative diagnostic tests in four clinical sites. A common
core protocol used by all four sites is itemized in Table 1.
Individual site protocols include complementary physiologic
and functional cardiovascular assessments (Table 2). The
study protocols were each approved by the site institutional
review boards. All women are followed for at least one year
to assess clinical events and symptom status.
The study is organized into three phases. Phase I (1996–
1997) was a pilot phase and enrolled 256 women. Data from
the common core protocol as well as individual site proto-
cols for this phase have been examined and protocol
revisions were made before proceeding to Phase II. Phase II
(1997–1999) is studying an additional 680 women, with a
total WISE enrollment of 936 women. Phase III (2000) will
Abbreviations and Acronyms
ECG 5 electrocardiogram/electrocardiographic
MRI 5 magnetic resonance imaging
SPECT 5 single photon emission computed
tomography
WISE 5 Women’s Ischemia Syndrome Evaluation
Table 1. Women’s Ischemia Syndrome Evaluation Common
Core Protocol
Testing and Data
Collection Core Lab
Demographic data Coordinating Center
Symptom
characterization
Coordinating Center
Psychosocial
characterization
Coordinating Center
Fasting blood sugar Coordinating Center
Fasting TC, TG,
HDL-C, LDL-C
Cedars-Sinai Medical Center
Lipid peroxidation University of Pittsburgh
Blood hormone levels Cedars-Sinai Medical Center
Phytoestrogen levels Cedars-Sinai Medical Center
Homocysteine levels University of Pittsburgh
Genetic analysis University of Pittsburgh
Left ventriculography Rhode Island Hospital
Coronary angiography Rhode Island Hospital
Resting ECG University of Pittsburgh
Exercise ECG St. Louis University, St. Louis
Ambulatory ECG University of Florida, Gainesville
Brachial artery reactivity
testing
University of Pittsburgh
MR spectroscopy University of Alabama at
Birmingham
ECG 5 electrocardiography; HDL-C 5 high density lipoprotein cholesterol;
LDL-C 5 low density lipoprotein cholesterol; MR 5 magnetic resonance; TC 5
total cholesterol; TG 5 triglycerides.
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include patient follow-up, data analysis and a National
Institutes of Health WISE workshop.
Study Recruitment and Inclusion/Exclusion Criteria
Women are eligible for participation if they are older than
18 years of age and are undergoing a clinically indicated
coronary angiogram as part of their regular medical care for
chest pain symptoms or suspected myocardial ischemia.
Major exclusion criteria include comorbidity which com-
promises one-year follow-up, pregnancy, contraindications
to provocative diagnostic testing, cardiomyopathy, New
York Heart Association class IV congestive heart failure,
recent myocardial infarction, significant valvular or congen-
ital heart disease and a language barrier to questionnaire
testing. Women with recent coronary angioplasty or coro-
nary bypass surgery or who undergo these procedures after
angiography but before their WISE testing are also ex-
cluded.
Common Core Protocol
All participants have data collected uniformly for a Com-
mon Core Protocol, as outlined in Figure 1. To characterize
symptoms, WISE compares a questionnaire of known
diagnostic validity in women (15) to a new symptom
questionnaire specifically developed for women (Hodgson
and Berry, personal communication, August 1996). Ques-
tions regarding initial response to symptoms and health
seeking behavior are included. Symptoms provoked during
testing procedures are assessed using a uniform tool. Psy-
chosocial assessment includes indicators of hostility/
cynicism (16), typical depression (17), panic (18), avoidance
(19), autonomic perception (20), reward dependence (21),
trait anxiety (22), social support (23) and quality of life.
Blood determinations include follicle-stimulating hor-
mone, luteinizing hormone, progesterone, estradiol, bio-
available estradiol, estrone, phytoestrogens, fasting blood
glucose, lipids, homocysteine, lipid peroxidation and de-
oxyribonucleic acid analysis.
Coronary angiography as assessed by a core laboratory
includes quantification of epicardial coronary artery size,
quantification of left ventricular ejection fraction and qual-
itative and quantitative assessment as to the presence,
severity and complexity of epicardial coronary artery steno-
ses, using a previously published coronary severity score
(24). The following definitions are used for coronary artery
group categorization: normal/minimal disease 5 ,20%
stenosis; mild 5 20% to 49% stenosis; significant 5 $50%
stenosis in any one major epicardial coronary artery. Resting
ECGs are interpreted by a core laboratory, using
Figure 1. Women’s Ischemia Syndrome Evaluation common core
testing flow diagram. CV 5 cardiovascular; ECG 5 electrocardi-
ography; LV 5 left ventricular; MR 5 magnetic resonance; P 5
phosphorus.
Table 2. Women’s Ischemia Syndrome Evaluation Site-Specific
Methodologies
AGH UAB FLA PGH
Echocardiography
Dobutamine stress X X
Exercise stress X
Magnetic resonance
imaging
CA X
Perfusion X
Spectroscopy (X) X (X) (X)
Nuclear scintigraphy
Dipyridamole stress X
99mTc sestamibi
Positron emission
tomography
Intravenous adenosine X
Mental stress X
Brachial artery reactivity X X X X
Provocative coronary
angiography
Intracoronary
acetylcholine
X
Doppler coronary flow
reserve
Intracoronary adenosine X X X
Mental stress X
Intravenous adenosine X
Intracoronary nitroglycerin X
(X) 5 implemented in Phase II. AGH 5 Allegheny General Hospital; CA 5
coronary angiography; FLA 5 University of Florida, Gainesville; PGH 5 University
of Pittsburgh Medical Center; UAB 5 University of Alabama at Birmingham.
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gender-specific interpretative criteria for left ventricular
hypertrophy (25). Data are also being collected, when
available, from routine clinical stress testing, including
nuclear perfusion imaging, performed before WISE enroll-
ment.
Ambulatory ECG monitoring is performed for 24 to 48 h
according to previously described methods (26), using an
all-digital recording system (27,28) with electronic transfer
of the data to a core laboratory for analysis and interpreta-
tion. Brachial artery reactivity testing for both endothelium-
dependent and endothelium-independent vasomotion is
performed using standard techniques (29), with data anal-
ysis by a core laboratory.
Follow-up
Women’s Ischemia Syndrome Evaluation participants are
contacted at six weeks and then annually to assess symptom
status, menstrual status and occurrence of cardiovascular
events, including death, nonfatal myocardial infarction,
coronary angioplasty, coronary bypass surgery, cardiac trans-
plantation and hospitalization for unstable angina.
Specific Protocols
The testing protocol methods are organized below accord-
ing to the three main WISE study goals. When testing is
performed at more than one site, a uniform protocol is used.
Interpretation of all studies is performed by masked observ-
ers for both qualitative and quantitative analysis.
Goal: to improve diagnostic testing for ischemic heart
disease in women. The innovative diagnostic tests selected
for the WISE represent the best technologic advances in
ischemic heart disease detection currently available. An
emphasis was placed on selection of techniques which might
obviate difficulties relevant to women, such as breast imag-
ing artifact (magnetic resonance imaging [MRI]-coronary
angiography, MRI perfusion imaging and sestamibi single
photon emission computed tomography [SPECT] perfu-
sion imaging), as well as techniques commonly available
currently (dobutamine stress echocardiography and exercise
stress testing).
MAGNETIC RESONANCE IMAGING CORONARY ANGIOGRA-
PHY IMAGING. Magnetic resonance imaging coronary an-
giography depicts both anatomic features and flow effects of
epicardial coronary artery stenoses using a 1.5-T Siemens
Vision (Schaumberg, Illinois) with echo-planar capability.
The patient is supine in a phased array thoracic coil for
approximately 40 min, with the need for breath-holding
eliminated. Depending on cardiac cycle length, 5 to 11
views per cycle are obtained. Tomographic slice thickness is
2 mm and stacks of 16 to 24 images are taken at a time,
which can be viewed as obtained or put into a three-
dimensional volume in any orientation desired for qualita-
tive analysis. Image quantitation is performed with com-
pound and curved plane reslicing and three-dimensional
projection images.
MAGNETIC RESONANCE IMAGING PERFUSION IMAGING.
Magnetic resonance imaging myocardial perfusion
imaging is performed using “first pass” gadolinium–
diethylenetriaminepenta-acetic acid and a 1.5-T Philips
ACS Gyroscan system (Best, The Netherlands). Cardiac
scout images (two- and four-chamber views) are acquired in
two orthogonal planes and dynamic imaging is initiated just
before the bolus of gadolinium and continues for 64
heartbeats. The BRISK (30) and interpolated keyhole (31)
imaging sequences developed by one of the sites (University
of Alabama at Birmingham) allow up to three or four
near-simultaneous short-axis images to be acquired during
each cardiac cycle. Imaging of left ventricular function is
also performed. Qualitative defects by MRI are determined
by describing regional signal intensity with that of the
region containing the highest signal intensity in predefined
regions. Quantitative analysis uses plots of MR signal
intensity versus location about the circumference of the
short-axis image.
SESTAMIBI SPECT IMAGING. Sestamibi SPECT myocardial
imaging is performed at baseline and during dipyridamole
infusion. Myocardial perfusion images are obtained on a
64 3 64 matrix using a single-head Siemens Orbitor
SPECT camera (Schaumberg, Illinois) with a high resolu-
tion parallel-hole collimator for sestamibi imaging. Imaging
is performed every 5° for 40 s over a 180° arc. Rest and
dipyridamole images with sestamibi are obtained 1 h after
injection. Qualitative and quantitative analyses are per-
formed, the latter using gender-specific normal limits.
DOBUTAMINE STRESS ECHOCARDIOGRAPHY. After acqui-
sition of baseline images in standard views, dobutamine
stress echocardiography is performed using published meth-
odology (32). Image analysis includes calculation of a wall
motion score index, which is the total score divided by the
number of segments visualized and scored.
EXERCISE STRESS ECG. After standard 12-lead ECG re-
cordings and blood pressure measurements at rest, the
Asymptomatic Cardiac Ischemia Pilot treadmill exercise
protocol is performed, since it provides continuous “ramp-
like” increases in work, using previously published methods
(26). Reports of symptoms, including chest pain or discom-
fort, are carefully elicited and recorded along with level of
perceived exertion using the Borg scale (33).
Goal: to study pathophysiologic mechanisms for isch-
emia in the absence of epicardial coronary artery steno-
ses. Testing protocols were designed to determine the
prevalence of this syndrome in women with normal or mild
stenoses using a reference standard test for ischemia (MR
spectroscopy) and to explore the pathophysiologic mecha-
nisms involved (microvascular coronary flow reserve and
endothelial function testing).
MAGNETIC RESONANCE SPECTROSCOPIC STUDY. 31Phos-
porus MR spectroscopy is a nonimaging direct biochemical
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assessment of phosphocreatine, adenosine triphosphate and
inorganic phosphate metabolites. The patient is placed
supine in a Philips 1.5-T ACS MRI system (Best, The
Netherlands), and the positioning of the 31P surface coil
over the heart is confirmed. After acquisition of a control
spectrum at rest, the subject squeezes and holds a handgrip
at 30% of maximum force for approximately 7 min, during
which time a second spectrum is obtained. After the period
of exercise, the subject is allowed to recover, another
spectrum is collected and the study is complete. Spectral
data are processed at a core laboratory using Philips soft-
ware, and include phosphocreatine/adenosine triphosphate
ratios and rate–pressure products during all phases as well as
average dynamometer output for the exercise phase.
MICROVASCULAR CORONARY FLOW RESERVE. In women
with normal or mild stenoses, the left anterior descending
coronary artery is uniformly studied. When appropriate, the
artery suspected as causing the abnormal diagnostic test
response is studied. After administration of systemic hepa-
rin, a 0.014- to 0.018-in. (0.036 to 0.046 cm) Doppler-
tipped guide wire is advanced into the target vessel, as
previously described (14). After baseline recordings, aden-
osine (18 mg diluted in 2 ml saline followed by 5 ml saline
flush) is hand-injected as a bolus via the coronary guiding
catheter, and recordings are repeated. Time-averaged peak
coronary blood flow velocity is assessed at baseline and after
intracoronary adenosine and nitroglycerin (200 mg). One
site (University of Pittsburgh) is also assessing this during a
speech mental stress task and intravenous adenosine. A
cineangiogram is performed immediately after measurement
of coronary blood flow velocity. Quantitative coronary
angiography is performed off-line to quantify epicardial
coronary cross-sectional area 5.2 mm distal to the guide wire
tip. Coronary flow reserve is computed as the ratio of post-
to preadenosine average peak velocity (14). Volumetric
blood flow calculations, using coronary lumen diameter
measured from the angiograms, is also performed using
previously reported techniques (34). The ratio of flow
during each intervention (speech task, intracoronary and
intravenous adenosine, intracoronary nitroglycerin) to base-
line is used as a standard to define coronary vasomotion in
the studied women.
CORONARY ARTERY ENDOTHELIAL FUNCTION. Two min-
utes after completion of maximum flow reserve (described
above), repeat baseline recordings are made. The infusion
catheter is primed with low dose (1026M) acetylcholine
(0.036 mg/ml). Acetylcholine is then infused at a rate of
2 ml/min for 3 min. Three minutes after the beginning of
the infusion, blood flow velocity, ECG and pressure record-
ings are obtained, and a left coronary cineangiogram is
recorded using hand-injected low osmolar, nonionic con-
trast material. The same volumes of contrast material and
the same optimal projection are used for each angiogram.
High dose (1024M) acetylcholine (3.5 mg/ml) is then
infused and after 3 min all recordings and an angiogram are
repeated. Five minutes after this, coronary flow velocity and
coronary angiography are obtained. Intracoronary nitroglyc-
erin (150 mg) is given as a bolus from a glass syringe through
the guide catheter. After 1 min, coronary angiography is
performed. Nitroglycerin is given last as a direct acting
Figure 2. Women’s Ischemia Syndrome Evaluation reproductive hormone status characterization diagram. FSH 5 follicle-stimulating
hormone; HRT 5 hormone replacement therapy; LH 5 luteinizing hormone; LMP 5 last menstrual period; OC 5 oral contraceptives;
PERIMENO 5 perimenopausal; POSTMENO 5 postmenopausal; PREMENO 5 premenopausal. *.3 months before study entry.
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dilator to counteract any residual vasoconstrictive effects of
acetylcholine and to assure a reference angiogram for
analysis of maximal coronary lumen diameter at each coro-
nary segment of interest.
POSITRON EMISSION TOMOGRAPHY IMAGING. Baseline
myocardial perfusion is quantified in each of the three
coronary artery distributions by 13N-NH3–positron emis-
sion tomography imaging using standard techniques
(35,36). Twenty millicuries of 13N-NH3 is injected at rest,
during a continuous infusion of intravenous adenosine
(140 mg/kg/min), and during performance of a mental stress
speech task. The speech task uses predetermined stress-
provoking scenarios (37), and consists of a 2-min prepara-
tion period followed by a 3-min speech. The first several
minutes of temporal data acquired as 13N-NH3 is distrib-
uted in the blood and myocardium are analyzed by a
previously validated two-compartment model to quantify
myocardial blood flow (38,39).
Goal: to evaluate the influence of menopausal status and
reproductive hormone levels on diagnostic testing re-
sults. This testing is designed to assess diagnostic test
reproducibility in women, determine sources of variability,
such as cyclical reproductive hormones, and investigate the
influence of reproductive hormonal status and hormone
therapy on diagnostic test response and symptomatic status.
HORMONAL STATUS DETERMINATION. The hormonal sta-
tus determination developed for WISE uses both historical
and single sampling blood hormonal characterization (Fig.
2). Premenopausal women also undergo menstrual cycle
phase (follicular, luteal, menstrual) determination using
estradiol, progesterone, follicle-stimulating hormone and
luteinizing hormone levels, at the time of WISE testing.
Information regarding hormone therapy, including estro-
genic, progestational and androgenic agents taken within
24 h of each WISE test are recorded.
REPRODUCIBILITY STUDIES. A randomly chosen 3% of the
WISE participants are undergoing repeat dobutamine stress
echocardiography, ECG exercise stress testing, ambulatory
ECG monitoring, brachial artery reactivity testing, blood
sampling and quality of life assessment within six months
after the initial testing period in the absence of intercurrent
cardiovascular event. Careful, repeat assessment of men-
strual history, hormone therapy use and blood hormone
levels are carried out.
Plan of Analysis
The planned WISE analyses based on the three main study
goals are outlined.
Goal: to improve diagnostic testing for ischemic heart
disease in women. Analyses will determine the sets of
characteristics and test results (symptom characterization,
diagnostic techniques, reproductive hormone status and
level) that optimally predict presence or absence of signifi-
cant epicardial coronary artery stenoses, as well as outcomes
(cardiac events and symptom status) during follow-up.
Preliminary modeling for this has begun with data from
patients entered into Phase I. This allows for assessment of
necessity for transforming data, and assessment of stability
of the models by comparing the model for Phase I with the
model for Phase II, and provides focus for analyses to be
performed when all data are available. Estimates of sensi-
tivity, specificity and predictive accuracy from derived in-
dexes will have 95% confidence intervals no wider than
67%, based on a minimum clinically defined subgroup
sample size of 200 for specific diagnostic tests. Due to the
referral nature of this symptomatic population, selection
bias(es) will be present which will probably influence con-
clusions regarding the various tests’ diagnostic accuracy.
Goal: to study pathophysiologic mechanisms and prog-
nosis of myocardial ischemia in the absence of epicardial
coronary artery disease. Women with evidence of myocar-
dial ischemia by 31P MR spectroscopy in the absence of
significant epicardial coronary artery stenoses will be com-
pared with women without evidence of myocardial isch-
emia, as well as with women with significant epicardial
coronary artery stenoses according to physiologic measures
such as coronary flow reserve and endothelial function.
Hormonal status, symptoms and psychosocial characteristics
will also be compared to explore potential pathophysiologic
mechanisms of myocardial ischemia in the absence of
epicardial coronary artery stenoses. Prediction of cardiovas-
cular events, as previously defined, during the 1- to 3-year
follow-up will include comparison of those with and with-
out significant epicardial coronary artery stenoses and/or
myocardial ischemia. The estimated population of 200
participants with myocardial ischemia by MR spectroscopy
is expected to have a relatively low annual event rate (,2%)
compared with the approximately 300 participants with
significant epicardial coronary artery disease with an esti-
mated cumulative event rate of 20%. Since these rates are
not likely to provide sufficient power to detect meaningful
differences in prognosis by baseline assessment, an extension
in the long-term follow-up of WISE participants is being
planned.
Goal: to evaluate the influence of menopausal status and
reproductive hormone levels on diagnostic testing re-
sults. Reproductive hormonal status (premenopausal, peri-
menopausal, postmenopausal and hormone replacement
therapy) and serum hormone levels will be analyzed as to
their influence on diagnostic test accuracy and reproducibil-
ity. Reproductive status and hormone levels will be analyzed
as to their influence on symptoms, as well as measures of
coronary flow, endothelial function and myocardial ischemia
measured by 31P MR spectroscopy. These measures will be
compared among hormonal status groups using analysis of
variance with factors of hormonal status and diagnostic test
results. Diameter change will also be related directly to
estrogen levels as well as to symptoms, the presence and
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magnitude of myocardial perfusion abnormalities, coronary
arterial microvascular and endothelial testing and hormonal
status using scatterplots and regression analyses.
RESULTS
Characteristics of the pilot phase participants. A total of
1,979 women were screened, of whom 450 (23%) were
eligible for study entry during the pilot phase between
November 15, 1996 and July 16, 1997. The three most
frequent exclusions were recent revascularization procedures
(n 5 257, 21%), contraindications to ischemia provocation
(n 5 254, 21%) and recent myocardial infarction (n 5 154,
12%). Among the 249 (55%) enrolled women, 23 (9%) of
subjects have been terminated from the study for reasons
that included revascularization procedures after study entry
but before WISE testing, contact with patient lost and
patient found to be ineligible/refused testing. There were
three deaths remote from the WISE protocol testing.
Characteristics for the initial 308 WISE participants are
listed in Table 3. These women with suspected ischemic
heart disease are compared with previously described pop-
ulations of women, including healthy women from the
Framingham Study (40), healthy postmenopausal women
from the Postmenopausal Estrogen/Progestin Interventions
study (41) and postmenopausal women with established
ischemic heart disease from the Heart and Estrogen/
Progestin Replacement Study (42). Table 3 documents that
the WISE protocol identifies a group of women with a
constellation of cardiac risk factors greater than that seen in
both healthy women and women with established ischemic
heart disease. Notably, minority recruitment is good at 21%.
Review of reproductive status demonstrates that 85% of
the pilot phase WISE participants were postmenopausal,
3% were perimenopausal and 11% were premenopausal.
Among these participants, 38% were current users of hor-
mone replacement therapy. Among the postmenopausal
women, 60% reported prior hysterectomy and among these
women, 50% also reported bilateral salpingo-oophorectomy.
Characterization of the chest pain symptoms revealed
that 35% reported typical angina, 60% reported atypical
angina and 45% reported daily/almost daily symptoms.
Ninety-one percent of the participants had a low functional
capacity of ,8 metabolic equivalents, measured by the
Duke Activity Score Index (43). Comorbid conditions are
frequent and included history of treatment for depression
(26%), autoimmune disease (20%), weight cycling (.10 lbs
[.4.54 kg] .3 times) (32%) and polycystic ovary disease
(8%).
Coronary angiography results in the first 323 WISE
participants revealed that 31% of the participants have
significant coronary artery stenoses ($50%) in any major
coronary artery, 32% have mild stenoses (20% to 49%) and
37% have no (,20%) stenoses. The cumulative frequency
distribution of the severity scores in the WISE participants
is depicted in Figure 3, and demonstrates that 50% have a
low severity score ,10. The average left ventricular ejection
fraction is 68% (range 23% to 86%), and the majority (87%)
are greater than 50%.
Table 3. Comparative Characteristics—WISE Phase I
Variable
Healthy Women,
Framingham—Women
(40) (n 5 1,627)
Menopausal,
PEPI (41)
(n 5 875)
Menopausal/CAD,
HERS (42)
(n 5 2,762)
Suspected CAD,
WISE—Phase I
(n 5 308)
Age (yr) (range) 49 (19–78) 56 (45–64) 67 (44–79) 59 (21–86)
Minority 0% 11% 11% 21%
.High school NA 82% 32% 35%
HTN 22% 6% 58% 57%
DM 2% 0.5% 19% 23%
Smoke 30% 13% 13% 20%
BMI (kg/m2) 25 6 5 26 6 5 28 30 6 6
SBP (mm Hg) 121 6 18 115 6 14 135 6 14 138 6 23
DBP (mm Hg) 77 6 10 72 6 8 73 6 10 77 6 13
FBS (mg/dl) 92 6 21 97 6 10 NA 118 6 53
TC (mg/dl) 207 6 43 224 6 30 NA 200 6 49
TG (mg/dl) 106 6 123 104 6 55 168 6 64 153 6 93
HDL-C (mg/dl) 59 6 14 63 6 16 50 6 13 53 6 13
LDL-C (mg/dl) 130 6 38 140 6 26 130 6 NA 116 6 41
TC/HDL 4.0 6 1.5 3.9 6 0.1 4.7 6 1.5 3.9 6 1.3
Menopausal NA 100% 100% 86%
HRT NA 0% 24%* 38%
*Use .3 months before study screening.
BMI 5 body mass index; CAD 5 coronary artery disease; DBP 5 diastolic blood pressure; DM 5 diabetes mellitus (medication or FBS .140 mg/dl); FBS 5 fasting blood
sugar; HDL-C 5 high density lipoprotein cholesterol; HERS 5 Heart and Estrogen/Progestin Replacement Study; HRT 5 hormone replacement therapy; HTN 5
hypertension (medication or SBP .140 mm Hg or DBP .95 mm Hg); LDL-C 5 low density lipoprotein cholesterol; NA 5 not available; PEPI 5 Postmenopausal
Estrogen/Progestin Interventions; SBP 5 systolic blood pressure; Smoke 5 current smoking; TC 5 total cholesterol; TG 5 triglycerides; WISE 5 Women’s Ischemia Syndrome
Evaluation.
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DISCUSSION
Initial pilot phase data indicate that the WISE protocol is
safe and feasible for identifying symptomatic women with
and without significant epicardial coronary artery stenoses.
Pilot data indicate that WISE participants have high
frequency of coronary artery disease risk factors and expe-
rience symptoms that are limiting, despite often minimal
epicardial coronary artery stenoses and preserved left ven-
tricular function.
Summary. Previous evidence suggests that gender-specific
differences exist in ischemic heart disease symptoms, detec-
tion and management. The WISE study is: 1) defining new,
comprehensive diagnostic strategies to evaluate women with
suspected ischemic heart disease; 2) exploring the patho-
physiology and significance of ischemia in the absence of
epicardial coronary stenoses, and 3) evaluating the role of
reproductive hormones on symptoms and diagnostic test
response. Phase II of the WISE is in progress.
APPENDIX: WISE PARTICIPANTS
Clinical Sites and Investigators
Allegheny General Hospital - MCP Hahnemann School
of Medicine, Pittsburgh: Nathaniel Reichek, MD (prin-
cipal investigator [PI]), Christopher Kramer, MD (coinves-
tigator [CoI]), Douglas Schulman, MD (CoI), Sinda Di-
anzumba, MD (CoI), Walter Rogers, MS (CoI), Bryan C.
Donohue, MD (CoI), James Joye, DO (CoI), Diane Vido
(coordinator [C]), Diana Lynn Pakstis, RN(C)
University of Alabama at Birmingham, Birmingham:
William J. Rogers, MD (PI), Gerald M. Pohost, MD
(CoI), Alfred A. Bartolucci, PhD (CoI), Vera Bittner, MD
(CoI), Joseph R. Logic, MD (CoI), Steven Buchthal, PhD
(CoI), Carol E. Cornell, PhD (CoI), Jan A. Denhollander,
PhD (CoI), Marc Doyle, PhD (CoI), Anthon R. Fuisz,
MD (CoI), Edward T. Martin, MD (CoI), Thomas D.
Paine, MD (CoI), Michelle L. Robbin, MD (CoI), Lindsey
Tauxe (CoI), Edward G. Walsh, PhD, MSPH (CoI),
Kathy Clay, RN(C), William C. Gamble III, RN(C),
Kathleen Armstrong, RN(C)
University of Florida, Gainesville: Carl J. Pepine, MD
(PI), Jannet Lewis, MD (CoI), Lang Lin, MD (CoI),
Eileen Handberg-Thurmond, PhD (CoI), Rick Kerensky,
MD (CoI), Keith Stone, MD (CoI), Susan McGorray,
PhD (CoI), Alix Baxter, MD (CoI), Alice Boyette (C)
University of Pittsburgh: Steven E. Reis, MD (PI),
Katherine Detre, MD, DrPH (CoPI), Richard Holubkov,
PhD (CoI), Flordeliza Villanueva, MD (CoI), Jane Owens,
PhD (CoI), Karen Matthews, PhD (consultant), Janine
Flory, PhD (CoI), A.J. Conrad Smith, MD (CoI), Daniel
Edmundowicz, MD (CoI), David Townsend, PhD (CoI),
Carolyn Meltzer, MD (CoI), Kathleen Zell, BSN (C),
Cheryl Rickens, RN(C)
Coordinating Center—University of Pittsburgh: Sheryl
F. Kelsey, PhD (PI), Katherine M. Detre, MD, DrPH
(CoI), Richard Holubkov, PhD (CoI), Tanya Kenkre,
MPH(C), Marian Olson, MS(C), B. Delia Johnson,
PhD(C)
Core Angiography Laboratory—Rhode Island Hospital:
Barry L. Sharaf, MD (PI), David O. Williams, MD (CoI),
Nicholas Miele (C)
National Heart, Lung and Blood Institute Project Of-
ficers: George Sopko, MD, Paul Albert, PhD, Gail Pear-
son, MD, Donna Berkowitz (contract C), William Stevens
(contract C), Doug Frye (contract C)
Study Chair—Cedars-Sinai Medical Center, Los Ange-
les: C. Noel Bairey Merz, MD (PI)
Data and Safety Monitoring Board: Bernard J. Gersh,
MD (Chair), Robert O. Bonow, MD, Richard O. Cannon
III, MD, Katherine Stoney, PhD, Madison Powers, PhD,
JD, Erica Brittain, PhD
Reprint requests and correspondence: Dr. C. Noel Bairey Merz,
c/o WISE Coordinating Center, University of Pittsburgh, 127
Parran Hall, Graduate School of Public Health, 130 DeSoto St.,
Pittsburgh, Pennsylvania 15261.
REFERENCES
1. Statistical Abstract of the United States. 112th ed. Washington (DC):
U.S. Department of Commerce, Economics and Statistics Adminis-
tration, Bureau of the Census, 1992.
2. DeStefano F, Merritt RK, Anda RF, et al. Trends in nonfatal coronary
heart disease in the United States, 1980 through 1989. Arch Intern
Med 1993;153:2489–94.
3. Tobin JN, Wassertheil-Smoller S, Wexler JP, et al. Sex bias in
considering coronary bypass surgery. Ann Intern Med 1987;107:19–
25.
4. Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the
noninvasive evaluation and management of patients with suspected
coronary artery disease. Ann Intern Med 1994;120:559–66.
Figure 3. Women’s Ischemia Syndrome Evaluation cumulative
frequency distribution of coronary artery severity scores.
1460 Bairey Merz et al. JACC Vol. 33, No. 6, 1999
The WISE Study May 1999:1453–61
5. Khan SS, Nessim S, Gray R, et al. Increased mortality of women in
coronary artery bypass surgery: evidence for referral bias. Ann Intern
Med 1990;112:561–7.
6. Krumholz HM, Douglas PS, Lauer MS, Pasternak RC. Selection of
patients for coronary angiography and coronary revascularization early
after myocardial infarction: is there evidence for a gender bias? Ann
Intern Med 1992;116:785–90.
7. Tofler GH, Stone PH, Muller JE, et al. Effects of gender and race on
prognosis after myocardial infarction: adverse prognosis for women,
particularly black women. J Am Coll Cardiol 1987;9:473–82.
8. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital
and 1-year mortality in 1524 women after myocardial infarction:
comparison with 4315 men. Circulation 1991;83:484–91.
9. The Principal Investigators of CASS and Their Associates. The
National Heart, Lung, and Blood Institute Coronary Artery Surgery
Study (CASS). Circulation 1981;63 Suppl 1:1–81.
10. Kennedy JW, Killip R, Fisher LD, et al. The clinical spectrum of
coronary artery disease and its surgical and medical management,
1974–1979. The Coronary Artery Surgery Study. Circulation 1982;66
Suppl 3:16.
11. Barolsky SM, Gilbert CA, Farugui A, et al. Differences in electrocar-
diographic response to exercise of women and men: a non-Bayesian
factor. Circulation 1979;60:1021–7.
12. Higgenbotham MB, Morris KG, Coleman E, Cobb FR. Sex related
differences in the normal cardiac response to upright exercise. Circu-
lation 1984;70:357–66.
13. Detrano R, Froelicher VF. Exercise testing: uses and limitations
considering recent studies. Prog Cardiovasc Dis 1988;31:173–204.
14. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely
attenuates abnormal coronary vasomotor responses to acetylcholine in
postmenopausal women. Circulation 1994;89:52–60.
15. Diamond GA, Staniloff HM, Forrester JS, et al. Computer-assisted
diagnosis in the noninvasive evaluation of patients with suspected
coronary artery disease. J Am Coll Cardiol 1983;1:444–55.
16. Cook WW, Medley DM. Proposed hostility and pharasaic virtue
scales for the MMPI. J Appl Psychol 1954;38:414 – 8.
17. Beck AT, Ward CH, Mendelsohn M, et al. An inventory for
measuring depression. Arch Gen Psychiatry 1961;4:561–71.
18. Schmidt NB, Telch MJ. The role of safety information and fear of
bodily sensations in moderating responses to a hyperventilation chal-
lenge. Behav Ther 1994;25:197–208.
19. Cloninger CR. A systematic method for clinical description and
classification of personality variants. Arch Gen Psychiatry 1987;44:
573–88.
20. Mandler G, Mandler J, Uviller E. Automatic feedback: the perception
of autonomic activity. J Abnorm Soc Psychol 1958;56:367–73.
21. Freedland KE, Carney RM, Krone RJ, et al. Psychological factors in
silent myocardial ischemia. Psychosom Med 1991;53:13–24.
22. Spielberger CD, Gorsuch RL, Lushene RD. Manual for the State-
Trait Anxiety Inventory. Palo Alto (CA): Consulting Psychologists
Press, 1970.
23. Cohen S, Doyle WJ, Skoner DP, et al. Social ties and susceptibility to
the common cold. JAMA 1997;277:1940–4.
24. Sharaf BL, Williams DO, Miele NJ, et al. A detailed angiographic
analysis in patients with ambulatory electrocardiographic ischemia:
results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study
Angiographic Core Laboratory. J Am Coll Cardiol 1997;29:78–84.
25. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardio-
graphic identification of left ventricular hypertrophy: test perfor-
mance in relation to definition of hypertrophy and presence of
obesity. J Am Coll Cardiol 1996;27:124 –31.
26. Pepine CJ, Geller NL, Knatterud GL, et al. The Asymptomatic
Cardiac Ischemia Pilot (ACIP) study: design of a randomized
clinical trial, baseline data and implications for a long-term
outcome trial. J Am Coll Cardiol 1994;24:1–10.
27. Hill JA, Bertolet BD, Duran A, et al. An ambulatory ECG monitoring
approach to the problems of ischemia-guided therapy. J Amb Monitor
1991;4:175–85.
28. Pepine CJ, Cohn PF, Deedwania PC, et al, for the ASIST Study
Group. Effects of treatment on outcome in mildly symptomatic
patients with ischemia during daily life. Circulation 1994;90:762–8.
29. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent
dilation in the systemic arteries of asymptomatic subjects relates to
coronary risk factors and their interaction. J Am Coll Cardiol 1994;
24:1468–74.
30. Doyle M, Walsh EG, Blackwell GG, Pohost GM. Block regional
interpolation scheme for k-space (BRISK): A rapid cardiac imaging
technique. Magn Reson Med 1995;33:163–70.
31. Walsh EG, Doyle M, Lawson MA, et al. Multislice first-pass
myocardial perfusion imaging on a conventional clinical scanner.
Magn Reson Med 1995;34:34–47.
32. Lewis J, Lin L, McGorray S, et al. Dobutamine stress echocardi-
ography in women with chest pain: pilot phase data from the
NHLBI Women’s Ischemia Syndrome Evaluation (WISE). J Am
Coll Cardiol 1999;33:1462– 8.
33. Borg G. Perceived exertion as an indicator of somatic stress. Scand J
Rehabil Med 1970;2-3:92–8.
34. Doucette JW, Corl D, Payne HM, et al. Validation of a Doppler guide
wire for intravascular measurement of coronary artery flow velocity.
Circulation 1992;85:1899–911.
35. Muller P, Czernin J, Choi Y, et al. Effect of exercise supplementation
during adenosine infusion on hyperemic blood flow and flow reserve.
Am Heart J 1994;128:52–60.
36. Krivokapich J, Smith JT, Huang S-C, et al. 13N Ammonia myocardial
imaging at rest and with exercise in normal volunteers. Quantification
of absolute myocardial perfusion with dynamic positron emission
tomography. Circulation 1989;80:1328–37.
37. Goldberg AD, Becker LC, Bonsall R, et al. Ischemic, hemodynamic,
and neurohumoral responses to mental and exercise stress: experience
from the Psychophysiological Investigations of Myocardial Ischemia
Study (PIMI). Circulation 1996;94:2402–9.
38. Choi Y, Huang SC, Hawkins RA, et al. A simplified method for
quantification of myocardial blood flow using nitrogen-13-
ammonia and dynamic PET. Circulation 1989;80:1328 –37.
39. Kuhle WG, Porenta G, Huang SC, et al. Quantification of regional
myocardial blood flow using 13N-ammonia and reoriented dynamic
positron emission tomographic imaging. Circulation 1992;86:1004–
17.
40. Lamon-Fava S, Wilson WF, Schaefer EJ. Impact of body mass index
on coronary heart disease risk factors in men and women. The
Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1996;
16:1509–15.
41. The Writing Group for the PEPI Trial. Effects of estrogen and
estrogen/progesting regimens on heart disease risk factors in post-
menopausal women: The Postmenopausal Estrogen/Progestin Inter-
ventions (PEPI) Trial. JAMA 1995;273:199–208.
42. Schrott HG, Bittner V, Bittinghoff E, et al. for the HERS Research
Group. Adherence to National Cholesterol Education Program treat-
ment goals in postmenopausal women with heart disease: The Heart
and Estrogen/Progestin Replacement Study (HERS). JAMA 1997;
277:1281–6.
43. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-
administered questionnaire to determine functional capacity (The
Duke Activity Status Index). Am J Cardiol 1989;64:651–4.
1461JACC Vol. 33, No. 6, 1999 Bairey Merz et al.
May 1999:1453–61 The WISE Study
